How Much Does Wegovy Cost in South Carolina in 2026?

Wegovy Retail Pricing Across South Carolina

The wholesale acquisition cost (WAC) for Wegovy is $1,349.02 per month across all maintenance dose tiers, set by Novo Nordisk and applied nationally [1]. South Carolina retail pharmacies, including CVS, Walgreens, and independent locations, list cash-pay prices at or near that WAC figure. Prices do not vary significantly between Charleston, Columbia, Greenville, or smaller markets because the WAC acts as a price floor for this single-source branded biologic.

Novo Nordisk increased the list price of Wegovy by 3.5% in January 2024 and held it steady through early 2026 [2]. The company has publicly stated that net prices (after rebates to insurers and pharmacy benefit managers) are lower than list, but uninsured patients or those with non-covering plans pay close to the full WAC [3]. A 2023 analysis published in JAMA found that the annual per-patient cost of branded GLP-1 receptor agonists exceeded $12 to 000 in the United States, placing these medications among the most expensive chronic-disease therapies on the market [4]. For South Carolina residents without coverage, this translates to roughly $16,188 per year at list price.

By comparison, the STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [5]. The clinical benefit is well established, but the cost barrier remains the primary obstacle to access in South Carolina and nationally [6].

South Carolina Medicaid and Wegovy

South Carolina's Medicaid program, administered through the SC Department of Health and Human Services (SCDHHS), does not cover Wegovy for chronic weight management as of May 2026. This exclusion aligns with a broader national pattern: a 2024 KFF analysis found that fewer than 15 states had any Medicaid coverage pathway for anti-obesity medications [7].

The exclusion stems from a longstanding federal provision. Until the Treat and Reduce Obesity Act gains full legislative traction, most state Medicaid programs retain the authority to exclude drugs used solely for weight loss from their formularies [8]. South Carolina exercises that authority. Semaglutide at the 0.25 mg to 1.0 mg doses (branded as Ozempic) is covered by SC Medicaid for type 2 diabetes, but the 2.4 mg weight-management formulation is not [9].

Patients on SC Medicaid who have type 2 diabetes and obesity may qualify for Ozempic. While the FDA-approved indication differs, prescribers sometimes document the diabetes indication as primary. The American Diabetes Association's 2024 Standards of Care note that GLP-1 receptor agonists offer dual benefit in patients with coexisting obesity and type 2 diabetes [10]. Patients should discuss this option with their prescriber, as Ozempic and Wegovy contain the same active molecule (semaglutide) but at different doses and with distinct labeling.

Insurance Coverage for Wegovy in South Carolina

Commercial insurance coverage for Wegovy in South Carolina varies by carrier, plan tier, and employer benefit design. BlueCross BlueShield of South Carolina, the state's dominant commercial insurer, covers Wegovy on select plans but requires prior authorization and documented failure of lifestyle intervention [11]. Typical prior authorization criteria include:

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
• Documentation of a structured diet and exercise program lasting ≥6 months
• No concurrent use of another GLP-1 receptor agonist

Other carriers operating in South Carolina, including Cigna, UnitedHealthcare, and Aetna, offer Wegovy coverage on certain employer-sponsored and marketplace plans. Coverage rates have expanded since the SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity [12]. The FDA added a cardiovascular risk reduction indication to the Wegovy label in March 2024, which prompted several large insurers to relax prior authorization requirements [13].

Patients with TRICARE (serving the large military population near Fort Jackson, Shaw Air Force Base, and Joint Base Charleston) gained Wegovy coverage in late 2024 following the cardiovascular indication expansion [14]. Federal Employees Health Benefits (FEHB) plans also increasingly cover the drug, giving federal workers in South Carolina another access route.

The Novo Nordisk Savings Card in South Carolina

Novo Nordisk offers a manufacturer savings card that reduces the out-of-pocket cost of Wegovy for commercially insured patients. The card provides up to $500 off per 28-day fill, with a maximum annual benefit that resets each calendar year [15]. Eligibility requirements are straightforward: the patient must have commercial insurance (not Medicare, Medicaid, or other government programs), and the prescription must be for an FDA-approved indication.

For a commercially insured patient whose plan covers Wegovy with a $150 copay, the savings card could reduce the monthly out-of-pocket cost to zero or near zero. For a patient whose plan does not cover Wegovy, the card still applies but only reduces the $1,349 list price by $500, leaving roughly $849 per month. The savings card does not apply to compounded semaglutide or to patients receiving government-funded insurance.

South Carolina residents can enroll at the Novo Nordisk patient assistance portal. Patients with household incomes below 400% of the federal poverty level who lack insurance coverage may also qualify for the Novo Nordisk Patient Assistance Program (PAP), which provides Wegovy at no cost [15]. The PAP requires annual income verification and prescriber attestation.

Compounded Semaglutide 2.4 mg in South Carolina

Licensed 503A compounding pharmacies in South Carolina can legally prepare semaglutide 2.4 mg formulations under current federal and state law. The FDA's regulatory framework permits 503A pharmacies to compound medications, including semaglutide, when they hold a valid patient-specific prescription and comply with state Board of Pharmacy requirements [16].

The average cost for compounded semaglutide 2.4 mg from a 503A pharmacy in South Carolina is approximately $199 per month. This represents an 85% reduction compared to branded Wegovy. The price difference reflects the absence of Novo Nordisk's brand premium, clinical trial amortization, and direct-to-consumer marketing costs.

Important caveats apply. Compounded semaglutide is not FDA-approved, meaning it has not undergone the same manufacturing consistency, sterility, and potency testing as branded Wegovy [17]. The FDA issued a safety communication in 2023 warning consumers about adverse events linked to compounded semaglutide products, including dosing errors and contamination [17]. Patients considering compounded semaglutide should verify that the pharmacy holds current 503A licensure through the South Carolina Board of Pharmacy and uses third-party potency and sterility testing.

The legal status of compounded semaglutide has been a moving target nationally. Novo Nordisk's semaglutide was placed on the FDA drug shortage list in 2022, which expanded compounding access. As of early 2026, the shortage status has been partially resolved for certain dose presentations, and the FDA has indicated that compounding eligibility may narrow [18]. South Carolina patients using compounded semaglutide should stay informed about federal regulatory changes that could affect availability.

Telehealth Prescribing of Wegovy in South Carolina

South Carolina permits telehealth prescribing of Wegovy under the state's Telemedicine Act (SC Code § 40-47-37). Physicians licensed in South Carolina or holding an appropriate interstate compact license can prescribe controlled and non-controlled substances via synchronous audio-video visits [19]. Semaglutide is not a DEA-scheduled substance, which simplifies the telehealth prescribing pathway compared to stimulant-based weight-loss medications.

Several national telehealth platforms operate in South Carolina and offer Wegovy prescriptions following virtual consultations. These platforms typically charge a consultation fee ($50 to $199) separate from the medication cost. Some bundle the consultation with compounded semaglutide at a combined monthly price, while others write prescriptions for branded Wegovy that patients fill at their local pharmacy.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity endorses GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI ≥30 or BMI ≥27 with comorbidities, and does not restrict the prescribing modality to in-person visits [20]. Telehealth prescribing of Wegovy is clinically appropriate when the provider conducts a thorough medical history, reviews current medications, and monitors treatment response at regular intervals.

How Wegovy Pricing in South Carolina Compares Nationally

South Carolina's Wegovy pricing mirrors the national average because Novo Nordisk sets a uniform WAC. The real variation occurs in out-of-pocket cost, which depends on insurance coverage, plan design, and pharmacy selection. States with broader Medicaid anti-obesity medication coverage (such as New York) offer access pathways that South Carolina does not [7].

A 2024 Institute for Clinical and Economic Review (ICER) analysis estimated the cost-effectiveness threshold for semaglutide 2.4 mg at $7,500 to $9,800 per year, well below the current list price of $16,188 [21]. ICER concluded that Wegovy's list price would need to decrease by 40% to 53% to meet conventional willingness-to-pay thresholds. For South Carolina's uninsured population (approximately 11.4% of adults under 65, per U.S. Census Bureau data), this pricing gap is especially acute [22].

The SELECT trial's cardiovascular findings have shifted the cost-effectiveness calculus. A secondary economic analysis of SELECT data, published in Circulation in 2024, found that semaglutide 2.4 mg reduced cardiovascular hospitalizations by 18%, generating potential downstream savings that partially offset the drug's acquisition cost [23]. Whether South Carolina Medicaid will incorporate these findings into future formulary decisions remains an open question.

Clinical Efficacy: What the Evidence Shows

Wegovy's efficacy profile is anchored by the STEP clinical trial program. STEP-1 (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo, with 86.4% of participants achieving ≥5% weight loss [5]. STEP-2 (N=1,210), conducted in adults with type 2 diabetes, showed 9.6% weight loss with semaglutide versus 3.4% with placebo [24].

The SELECT trial extended the evidence base to cardiovascular outcomes. Among 17,604 adults aged 45 or older with established cardiovascular disease and BMI ≥27 (without diabetes), semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% (hazard ratio 0.80 to 95% CI 0.72 to 0.90, P<0.001) over a mean follow-up of 39.8 months [12].

"Semaglutide 2.4 mg represents the first anti-obesity medication to demonstrate a reduction in major adverse cardiovascular events in a dedicated outcomes trial," noted Dr. A. Michael Lincoff, principal investigator of SELECT, in the New England Journal of Medicine [12].

The American Association of Clinical Endocrinology (AACE) 2024 obesity algorithm positions GLP-1 receptor agonists as first-line pharmacotherapy alongside lifestyle modification for patients meeting BMI criteria [25]. The AACE guideline specifically names semaglutide 2.4 mg as having the strongest evidence base among currently approved agents.

Practical Steps to Reduce Wegovy Cost in South Carolina

South Carolina patients have several strategies to lower their Wegovy expenses. First, confirm insurance coverage and prior authorization requirements by calling the number on the back of the insurance card. Second, enroll in the Novo Nordisk savings card program if commercially insured. Third, explore the Novo Nordisk Patient Assistance Program if uninsured and income-eligible [15].

For patients who cannot afford branded Wegovy, compounded semaglutide from a licensed 503A pharmacy offers a lower-cost alternative at roughly $199 per month. Verify the pharmacy's licensure through the South Carolina Board of Pharmacy before filling a prescription [16].

"Clinicians should discuss cost openly with patients and present all available access pathways, including manufacturer programs, insurance appeals, and compounded alternatives, as part of shared decision-making," states the Obesity Medicine Association's 2024 clinical practice statement [26].

Patients denied coverage should request a formal denial letter and file an appeal. Including SELECT trial cardiovascular data and AACE guideline recommendations in the appeal strengthens the medical necessity argument. South Carolina's Department of Insurance oversees the external appeal process for fully insured commercial plans [27].